Neurology

The CGTLive^™ Neurology specialty topic page houses video interviews with key opinion leaders in the field of neurology about the latest relevant FDA actions, clinical guideline updates, and clinical trial findings related to cell therapies, gene therapies, and engineered and regenerative medicines developed for neurologic disorders and diseases. It also contains up-to-date clinical news coverage in the field of gene and cell therapy for central nervous system disorders.

Latest News

Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center

Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma

By Bhagirathbhai Dholaria, MBBS
Noah Stansfield

November 21st 2024

Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center, discussed interim data from the phase 1/1b clinical trial evaluating Poseida's CAR-T.

Around the Helix: Cell and Gene Therapy Company Updates – November 20, 2024

By Noah Stansfield

November 20th 2024

Sophie Olivier, MD, the chief medical officer of Atamyo

Atamyo Therapeutics' Gene Therapy ATA-200 Cleared for US Trial in LGMD Type 2C/R5

By Noah Stansfield

November 19th 2024

Rachel McMinn, PhD, the founder and chief executive officer of Neurogene

Patient Treated With Neurogene’s Investigational Rett Syndrome Gene Therapy NGN-401 in Critical Condition After Developing Life-Threatening Immune Response

By Noah Stansfield

November 18th 2024

CGTLive®’s Weekly Rewind – November 15, 2024

By CGTLive Staff

November 15th 2024

Latest CME Events & Activities

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

More News

Around the Helix: Cell and Gene Therapy Company Updates - February 16, 2022

Victoria Johnson

February 16th 2022

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Gene Therapy for Friedreich Ataxia Cardiomyopathy Set to Move Forward

Alicia Bigica

February 16th 2022

The FDA has approved LEXEO Therapeutics’ investigational new drug application.

Gene Therapy Well-Tolerated in Late-Onset Pompe Disease

Abby Reinhard

February 13th 2022

Interim safety data from the FORTIS study were presented at WORLDSympsoium.

Fibroblast Cell Therapy or Stem Cell Therapy for MS: Hamid Khoja, PhD

Hamid Khoja, PhD

February 11th 2022

The chief scientific officer of FibroBiologics discussed the advantages of fibroblast cell therapy over stem cell therapy.

Gene Therapy Stabilizes Disease Progression in GM1 Gangliosidosis

Victoria Johnson

February 10th 2022

Positive results from a phase 1/2 study of AXO-AAV-GM1 were presented at WORLDSymposium.

Around the Helix: Cell and Gene Therapy Company Updates - February 9, 2022

Victoria Johnson

February 9th 2022

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Gene and Cell Therapy Company Updates - February 2, 2022

Victoria Johnson

February 2nd 2022

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.

IND Cleared for Adrenomyeloneuropathy Gene Therapy

Victoria Johnson

February 2nd 2022

SwanBio previously presented positive preclinical data at the ESGCT 2021 meeting.

Giant Axonal Neuropathy Gene Therapy Well-Tolerated in High-Dose Cohort

Victoria Johnson

January 31st 2022

The positive news is countered by a report of a patient death in Taysha’s gene therapy program for GM2 gangliosidosis.

GeneTherapyLive’s Weekly Rewind – January 28, 2022

GeneTherapyLive Staff

January 28th 2022

Review top news and interview highlights from the week ending January 28, 2022.

Around the Helix: Gene and Cell Therapy Company Updates - January 26, 2022

Victoria Johnson

January 26th 2022

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.

Stem Cell Gene Therapy Efficacious in Metachromatic Leukodystrophy

Giuliana Grossi

January 25th 2022

Investigators from IRCCS San Raffaele analyzed results from a phase 1/2 study on atidarsagene autotemcel.

Around the Helix: Gene and Cell Therapy Company Updates - January 19, 2022

Victoria Johnson

January 19th 2022

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.

FDA Extends BLA Review for bluebird bio’s β-Thalassemia and CALD Gene Therapies

Victoria Johnson

January 18th 2022

Eli-cel remains on clinical hold in cerebral adrenoleukodystrophy after a report of persistent anemia.

GeneTherapyLive’s Weekly Rewind – January 14, 2022

GeneTherapyLive Staff

January 14th 2022

Review top news and interview highlights from the week ending January 14, 2022.

Around the Helix: Gene and Cell Therapy Company Updates

Victoria Johnson

January 11th 2022

Many cell and gene therapy companies are initiating new programs and collaborations with the start of the new year.

Gene Therapy Continues to Show Efficacy in Duchenne Muscular Dystrophy

Victoria Johnson

January 11th 2022

The placebo crossover cohort experienced statistically significant improvements in NSAA score over external control.

GeneTherapyLive’s Weekly Rewind – January 7, 2022

GeneTherapyLive Staff

January 7th 2022

Review top news and interview highlights from the week ending January 7, 2022.

Angelman Syndrome Gene Therapy Well Tolerated

Victoria Johnson

January 6th 2022

The DSMB has recommended that enrollment expand and doses be escalated from 3.3 to 5 mg in 1 cohort of the KIK-AS study.

AMT-130 for Huntington Disease Well-Tolerated

Matt Hoffman

January 4th 2022

Data from a phase 1/2 trial of AMT-130 supports continued enrollment for a higher-dose cohort of 6 x 1013 vg.

Strategies to Reverse Multiple Sclerosis Neurodegeneration: Robert Zivadinov, MD, PhD

Robert Zivadinov, MD, PhD

December 30th 2021

The director of the Buffalo Neuroimaging Analysis Center and professor of Universtiy of Buffalo discussed avenues of research into reversing neurodegeneration in MS.